Drug Trial Radar · NCT06224348
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids
Last checked: Nov 19, 2026Latest source record: Aug 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
643
Actual
Start
Jan 18, 2024
Primary completion
Aug 21, 2025
Study completion Nov 1, 2025
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Jan 25, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a parallel group, Phase 3, multinational, multicenter, randomized, double-blind, placebo controlled, 3-arm study for treatment of participants diagnosed with moderate-to-severe atopic dermatitis (AD) with a history of inadequate response of topical treatment, on background topical corticosteroid (TCS) and/or topical calcineurin inhibitor (TCI). The purpose of this study is to measure the efficacy and safety of treatment with amlitelimab solution for subcutaneous (SC) injection compared with placebo in participants with moderate to severe AD aged 12 years and older on background TCS and/or TCI. Study details include: At the end of the treatment period, participants will have an option to enter a separate study: the blinded extension study EFC17600 (ESTUARY). For participants not entering the blinded extension Study EFC17600 (ESTUARY), the study duration will be up to 44 weeks including a 2 to 4-week screening, a 24-week randomized double-blind period, and a 16-week safety follow-up. For participants entering the blinded extension Study EFC17600 (ESTUARY), the study duration will be up to 28 weeks including a 2 to 4-week screening and a 24-week randomized double-blind period. The total treatment duration will be up to 24 weeks. The total number of visits will be up to 10 visits (or 9 visits for those entering the blinded extension study EFC17600 (ESTUARY).
Conditions
- Dermatitis Atopic
Interventions
AmlitelimabDrug
Pharmaceutical form: Injection solution Route of administration: SC injection
PlaceboDrug
Pharmaceutical form: injection solution Route of administration: SC injection
Topical corticosteroidsDrug
Pharmaceutical form: Topical formulation Route of administration: Topical
Topical calcineurin inhibitorsDrug
Pharmaceutical form: Topical formulation Route of administration: Topical
Primary outcomes
What the sponsor says the trial is designed to measure.
- EU, EU reference countries, and Japan: Proportion of participants with Validated Investigator Global Assessment scale for Atopic Dermatitis (vIGA-AD) of 0 (clear) or 1 (almost clear) and a reduction from baseline of ≥2 points at Week 24Time frame: Week 24
- EU, EU reference countries, and Japan: Proportion of participants reaching 75% reduction from baseline in Eczema Area and Severity Index (EASI) score (EASI-75) at Week 24Time frame: Week 24
- US and US reference countries: Proportion of participants with vIGA-AD of 0 (clear) or 1 (almost clear) and a reduction from baseline of ≥2 points at Week 24Time frame: Week 24
Locations
167 sites in 14 countries. Site status is shown where the registry gives one.
Cahaba Dermatology & Skin Health Center- Site Number : 8401066
Birmingham, Alabama
Johnson Dermatology- Site Number : 8401076
Fort Smith, Arkansas
Encino Research Center- Site Number : 8401042
Encino, California
Marvel Clinical Research- Site Number : 8401102
Huntington Beach, California
LA Universal Research Center- Site Number : 8401064
Los Angeles, California
Cura Clinical Research- Site Number : 8401141
Palmdale, California
Integrative Skin Science and Research- Site Number : 8401275
Sacramento, California
Southern California Dermatology- Site Number : 8401043
Santa Ana, California
Skin Care Research - Hollywood- Site Number : 8401071
Hollywood, Florida
Clever Medical Research- Site Number : 8401160
Miami, Florida
Acevedo Clinical Research Associates- Site Number : 8401088
Miami, Florida
Palm Springs Community Health Center- Site Number : 8401264
Miami Lakes, Florida
Global Clinical Professionals (GCP)- Site Number : 8401045
St. Petersburg, Florida
University of South Florida- Site Number : 8401070
Tampa, Florida
Avita Clinical Research- Site Number : 8401073
Tampa, Florida
Cleaver Medical Group- Site Number : 8401138
Dawsonville, Georgia
NorthShore University HealthSystem - Skokie Hospital- Site Number : 8401038
Skokie, Illinois
Dawes Fretzin Clinical Research- Site Number : 8401015
Indianapolis, Indiana
BRCR Global Gretna- Site Number : 8401243
Gretna, Louisiana
Velocity Clinical Research - New Orleans- Site Number : 8401155
New Orleans, Louisiana
Oakland Medical Center- Site Number : 8401116
Troy, Michigan
Allergy & Immunology Associates of Ann Arbor- Site Number : 8401078
Ypsilanti, Michigan
Dermatology and Skin Cancer Lee's Summit- Site Number : 8401157
Lee's Summit, Missouri
Skin Specialists- Site Number : 8401068
Omaha, Nebraska
Jubilee Clinical Research- Site Number : 8401054
Las Vegas, Nevada
Allcutis Research - Portsmouth- Site Number : 8401082
Portsmouth, New Hampshire
Equity Medical- Site Number : 8401239
New York, New York
Icahn School of Medicine at Mount Sinai- Site Number : 8401129
New York, New York
OptiSkin- Site Number : 8401163
New York, New York
Apex Clinical Research Center- Site Number : 8401237
Mayfield Heights, Ohio
Essential Medical Research- Site Number : 8401183
Tulsa, Oklahoma
Vial Health - DermDox Dermatology- Site Number : 8401031
Camp Hill, Pennsylvania
Clinical Research Center of the Carolinas- Site Number : 8401067
Charleston, South Carolina
SMS Clinical Research- Site Number : 8401182
Mesquite, Texas
Sienna Dermatology- Site Number : 8401148
Missouri City, Texas
Texas Dermatology and Laser Specialists- Site Number : 8401131
San Antonio, Texas
Discovery Clinical Trials - San Antonio - Stone Oak Parkway- Site Number : 8401026
San Antonio, Texas
Complete Dermatology - Sugar Land- Site Number : 8401061
Sugar Land, Texas
Cope Family Medicine - Ogden Clinic- Site Number : 8401114
Bountiful, Utah
Tanner Clinic - Layton Antelope A- Site Number : 8401151
Layton, Utah
Showing 40 of 167 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.